about
A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyaseAn Oak Ridge legacy: the specific locus test and its role in mouse mutagenesisCarcinogenic effects in a phenylketonuria mouse modelA murine model for human sepiapterin-reductase deficiencyBehavioral and neurochemical characterization of new mouse model of hyperphenylalaninemiaMouse model resources for vision research.Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) miceThe Behavioral Consequence of Phenylketonuria in Mice Depends on the Genetic BackgroundPhenylketonuria: old disease, new approach to treatment.A strategy to identify dominant point mutant modifiers of a quantitative trait.Functional annotation of mammalian genomic DNA sequence by chemical mutagenesis: a fine-structure genetic mutation map of a 1- to 2-cM segment of mouse chromosome 7 corresponding to human chromosome 11p14-p15.ENU Mutagenesis in the Mouse.Complete and persistent phenotypic correction of phenylketonuria in mice by site-specific genome integration of murine phenylalanine hydroxylase cDNA.An olfactory discrimination procedure for mice.A sensitive assay system to test antisense oligonucleotides for splice suppression therapy in the mouse liver.Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of Phenylketonuria.State-of-the-art 2003 on PKU gene therapy.Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver.Assessing autism-like behavior in mice: variations in social interactions among inbred strains.Pathologic and immunohistochemical findings in hypothalamic and mesencephalic regions in the pah(enu2) mouse model for phenylketonuria.PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) miceFormulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuriaCardiac teratogenicity in mouse maternal phenylketonuria: defining phenotype parameters and genetic background influencesBiochemical, Metabolic, and Behavioral Characteristics of Immature Chronic Hyperphenylalanemic Rats.Dissecting innate immunity by germline mutagenesis.Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuriaGene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.Forward genetic screens to identify circadian rhythm mutants in mice.Metabolic engineering as therapy for inborn errors of metabolism--development of mice with phenylalanine hydroxylase expression in muscle.Cerebral protein synthesis in a genetic mouse model of phenylketonuriaForward and reverse genetic approaches to behavior in the mouse.Innate immunity and the new forward genetics.The PAH mutation analysis consortium database: update 1996.Interpretation of the mouse electroretinogram.Maternal Phenylketonuria syndrome: Studies in mice suggest a potential approach to a continuing problem.Metabolic etiologies in West syndrome.Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria.Improved Lentiviral Gene Delivery to Mouse Liver by Hydrodynamic Vector Injection through Tail Vein
P2860
Q28343191-AADC4940-89D3-48D5-978E-FD8C34BBFE66Q28379338-870E7037-604C-42E1-94C5-9AAFC2DB59E2Q28474582-6412C9A3-BB6F-47A3-99E6-688EE7E0FC38Q28510192-978E7E34-35A5-4F9F-840F-0DDA4FE77398Q28537886-EB54EBBC-9E8B-4D93-A420-54212F72977CQ29347298-D85F5C91-2CE4-4BC3-90E1-1C9744D49A3FQ30415470-C5079252-83B9-464A-8D72-2BA53B4CE1A6Q30832402-EAD299BA-3401-4280-B53E-171E32D22AC1Q33537485-98A989BD-4174-42D0-9B91-FA1794C93AE2Q33784960-2C904571-CC30-485B-83A0-AF02A0CE6268Q33894561-F854E788-462E-40DE-B774-463F333549B0Q33964080-0B407033-6BF4-4158-8DC7-FC8A9CB40689Q34098361-13951DEC-BF10-4043-9C46-D8650473D4E1Q34136453-5A502DD2-1556-4306-B19B-09A68E25503EQ34464418-9E7A151B-2DB3-4FF8-BE61-F265C0744874Q35490408-7B9D578B-5239-4CF6-AC76-D160673BCA00Q35631781-978D6022-4B85-45F7-BA76-255ACA2B2631Q35667391-AC46881C-2C11-41C8-8BC5-8AA7BFC13F80Q35697120-5FF12DE0-516A-4592-A1DD-D4E12F70763AQ35810261-CAB2264C-7F4F-4BAA-ADF4-5AE0F98D64ACQ36011470-D2CBC2C3-4F00-41B0-BDB8-FFF6151AB609Q36304253-F6EF4BC9-233A-4094-B810-05D37A63D578Q36417290-3769325E-3A6E-4EE3-8B0C-A1BAF2363D69Q36522138-6949B4E3-507A-40FD-95A5-2C35995EE2C2Q37060493-54451282-65E1-40B4-B445-E925A46E69A9Q37081629-48311564-8291-4F6A-BE58-7B0EB61193CFQ37127238-A8BC2417-601D-4D01-B2BE-5AA8E76D1766Q37131758-A9E57459-C7A3-4955-AFB8-8722D1AA0CEBQ37221662-C7179E72-0706-4401-A360-2B8E50ED5EB6Q37270493-B3FD965B-BB91-45A9-BAA5-AB4E2679E20AQ37316585-EDCFB1DB-B6D0-4397-BC82-5BE19793AED1Q39021390-ADAA8630-4F51-4730-8375-80390589D80BQ39718722-A90CB1D8-B392-4A69-9713-38DCA6643C58Q41833858-75027C3E-85D0-4EB9-91B8-770B235851C1Q47248016-06C0A056-598B-4530-9D80-967ECF0F68A9Q55235450-7CEC4617-1CA0-4137-BE06-4384BF90C0CFQ55352164-D9B92A63-8446-43D3-BCE9-1CFCF19ED5FFQ58799285-E16E3947-7A0E-4559-AB1E-07FBD1475C42
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Mouse models of human phenylketonuria.
@ast
Mouse models of human phenylketonuria.
@en
type
label
Mouse models of human phenylketonuria.
@ast
Mouse models of human phenylketonuria.
@en
prefLabel
Mouse models of human phenylketonuria.
@ast
Mouse models of human phenylketonuria.
@en
P2093
P2860
P1433
P1476
Mouse models of human phenylketonuria.
@en
P2093
A Shedlovsky
J D McDonald
P2860
P304
P407
P577
1993-08-01T00:00:00Z